<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop(Peter MacCallum Cancer Centre), Gillian Mitchell(Peter MacCallum Cancer Centre), Penelope M. Webb(Queensland Health), Michael Friedländer(University of Sydney), Alexander Dobrovic(Ludwig Cancer Research), Anna DeFazio(Peter MacCallum Cancer Centre), David D.L. Bowtell(Peter MacCallum Cancer Centre), Cliff Meldrum(John Hunter Hospital), Joshy George(The JAX Cancer Center), Sián Fereday(Peter MacCallum Cancer Centre), Stephen B. Fox(Peter MacCallum Cancer Centre), Michael J. Birrer(Center for Cancer Research), Catherine Emmanuel(Peter MacCallum Cancer Centre), Colin J.R. Stewart(King Edward Memorial Hospital)
Cited by 1,173
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k